Zileuton
From Wikipedia, the free encyclopedia
![]() |
|
|
Zileuton
|
|
| Systematic (IUPAC) name | |
| 1-(1-benzothiophen-2-ylethyl)-1-hydroxy-urea | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H12N2O2S |
| Mol. mass | 236.291 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Not yet established |
| Protein binding | 93% |
| Metabolism | Hepatic (CYP1A2, CYP2C9 and CYP3A4-mediated) |
| Half life | 2.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | Oral |
Zileuton (INN) is an asthma drug. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway.
Zileuton is marketed by Critical Therapeutics under the brand name Zyflo. As of February 20th, 2008, Zyflo tablets are to be discontinued, although Zyflo CR is still available [1]
[edit] See also
[edit] External links
[edit] References
|
||||||||||||||||||||||||||


